SEC Company Response from TENAX THERAPEUTICS, INC. (TENX) (CIK 0000034956) (TENX) — Dec 6, 2018
TENAX THERAPEUTICS, INC. (TENX) (CIK 0000034956)
Date: Dec. 6, 2018 · CIK: 0000034956 · Accession: 0001654954-18-013649
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-228212
Letter
VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance Tenax Therapeutics, Inc. Registration Statement on Form S-1 No. 333-228212 Withdrawal of Request for Acceleration
Dear Mr. Regan:
Reference is made to our letter, filed as correspondence via EDGAR on December 4, 2018, in which we requested the acceleration of the effective date of the above-referenced Registration Statement for Thursday, December 6, 2018, at 4:30 p.m. Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.
If you have any questions, please contact me at (919) 855-2123. Thank you in advance for your assistance.
Sincerely,
/s/
Michael B. Jebsen
Show Raw Text
CORRESP 1 filename1.htm Blueprint December 6, 2018 VIA EDGAR TRANSMISSION Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-0306 Attn: Ruairi Regan Division of Corporation Finance Re: Tenax Therapeutics, Inc. Registration Statement on Form S-1 No. 333-228212 Withdrawal of Request for Acceleration Dear Mr. Regan: Reference is made to our letter, filed as correspondence via EDGAR on December 4, 2018, in which we requested the acceleration of the effective date of the above-referenced Registration Statement for Thursday, December 6, 2018, at 4:30 p.m. Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date. If you have any questions, please contact me at (919) 855-2123. Thank you in advance for your assistance. Sincerely, /s/ Michael B. Jebsen Michael B. Jebsen President and Chief Financial Officer cc: Margaret N. Rosenfeld Partner, Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P.